Synthesis of vinyl protected alcohol intermediates

By mixing compounds B and C in an organic solvent and reacting with a reducing agent to form compound D, the problem of insufficient yield and purity of compounds A1 and A2 synthesis is solved, and efficient commercial production is achieved.

CN118908912APending Publication Date: 2024-11-08AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410970601.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-05-06
Filing Date
2021-04-27
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, the yield and purity of the synthesis method of compounds A1 and A2 are insufficient, making it difficult to meet the needs of commercial production.

Method used

Compounds B and C are mixed in an organic solvent to form a slurry and reacted with a reducing agent to form compound D. The synthesis is performed by one-step method without the need to separate the intermediate, which improves the yield and purity.

Benefits of technology

The high yield and high purity synthesis of compounds A1 and A2 is achieved, the process flow is simplified, and the stability and separation efficiency of the intermediate are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908912A_ABST
    Figure CN118908912A_ABST
Patent Text Reader

Abstract

The invention relates to the synthesis of vinyl protected alcohol intermediates. Provided herein are methods for the synthesis of intermediates useful in the preparation of Mcl-1 inhibitors. In particular, provided herein are methods for the synthesis of Compound D wherein OPG and R1 are described herein. The compound D can be used for synthesizing a salt of a compound A1 or a solvate thereof, and a salt of a compound A2 or a solvate thereof. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a patent application with application number 202180032830.0, application date April 27, 2021, and invention name “Synthesis of Vinyl-Protected Alcohol Intermediates”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 020,862, filed May 6, 2020, which is hereby incorporated by reference in its entirety and for all purposes as if fully set forth herein. Technical Field

[0004] The present disclosure relates to methods for synthesizing intermediates for synthesizing (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0 3,6 .0 19,24 ]pentacosa[8,16,18,24]tetraene]-15'-one 13',13'-dioxide (Compound A1; AMG 176), its salts or solvates, and (1S,3'R,6'R,7'R,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-7'-((9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-ylmethyl)-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0 3,6 .0 19,24 ]pentacosa[8,16,18,24]-tetraene]-15'-one 13',13'-dioxide (Compound A2; AMG 397), a salt or solvate thereof. These compounds are inhibitors of myeloid cell leukemia 1 protein (Mcl-1). Background Art

[0005] Compound (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0 3,6 .0 19,24]pentacosa[8,16,18,24]tetraene]-15'-one 13',13'-dioxide (Compound A1) is used as an inhibitor of myeloid cell leukemia 1 (Mcl-1):

[0006]

[0007] Compound (1S,3'R,6'R,7'R,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-7'-((9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-ylmethyl)-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0 3,6 .0 19,24 ]pentacosa[8,16,18,24]tetraene]-15'-one 13',13'-dioxide (Compound A2) is used as an inhibitor of myeloid cell leukemia 1 (Mcl-1):

[0008]

[0009] A common feature of human cancers is the overexpression of Mcl-1. Mcl-1 overexpression prevents cancer cells from undergoing programmed cell death (apoptosis), allowing these cells to survive despite extensive genetic damage.

[0010] Mcl-1 is a member of the Bcl-2 protein family. The Bcl-2 family includes pro-apoptotic members (such as BAX and BAK), which form homo-oligomers in the outer membrane of mitochondria after activation, which leads to pore formation and leakage of mitochondrial contents, a step that triggers apoptosis. Anti-apoptotic members of the Bcl-2 family (such as Bcl-2, Bcl-XL and Mcl-1) block the activity of BAX and BAK. Other proteins (such as BID, BIM, BIK and BAD) show additional regulatory functions. Studies have shown that Mcl-1 inhibitors can be used to treat cancer. Mcl-1 is overexpressed in many cancers.

[0011] US Patent No. 9,562,061, which is incorporated herein by reference in its entirety, discloses Compound A1 as a Mcl-1 inhibitor and provides a method for preparing the same. However, improved synthetic methods that produce greater yields and purity of Compound A1 are needed, particularly for commercial production of Compound A1.

[0012] US Patent No. 10,300,075, which is incorporated herein by reference in its entirety, discloses Compound A2 as a Mcl-1 inhibitor and provides a method for preparing the same. However, improved synthetic methods that produce greater yields and purity of Compound A2 are needed, particularly for commercial production of Compound A2. Summary of the invention

[0013] This article provides a method for synthesizing compound D:

[0014]

[0015] The method comprises (a) mixing compound B, or a salt thereof, and compound C in an organic solvent to form a slurry, wherein the organic solvent is selected from the group consisting of a non-polar aromatic solvent, an ether solvent, a chlorinated solvent, an alcohol solvent, acetonitrile, dimethylformamide (DMF), dimethyl carbonate, dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), and a combination thereof:

[0016]

[0017] (b) mixing the slurry of step (a) and a reducing agent to form a mixture comprising compound D; wherein: OPG is an alcohol protecting group selected from the group consisting of: ether, acetal or ketal, acyl, sulfonyl, and silyl ether; R 1 Is H or C 1-6 alkyl; and R 2 It is a protected aldehyde.

[0018] In various embodiments, the methods further include In step (a) it is mixed into an organic solvent.

[0019] In various embodiments, compound B is a salt. In various embodiments, R 1 is H. In various embodiments, R 1 It is methyl, ethyl, n-propyl, or tert-butyl.

[0020] In various embodiments, the OPG is selected from the group consisting of: (methoxy), (tert-butyl ether), (methoxymethyl acetal, MOM), (2-methoxyethoxymethyl ether, MEM), (ethoxyethyl acetal, EE), (methoxypropyl acetal, MOP), (tetrahydropyranyl acetal, THP), (benzyloxymethyl acetal, BOM), (benzyl ether, Bn), (4-methoxybenzyl ether, PMB), (2-naphthyl methyl ether, Nap), (Acetyl, Ac), Pivaloyl (Piv), (benzoyl, Bz), (4-bromobenzoyl, Br-Bz), (4-fluorobenzoyl), (4-chlorobenzoyl), (4-iodobenzoyl), (4-nitrobenzoyl), (4-phenylbenzoyl), (1-naphthoyl ester), (2-naphthoyl ester), (4-methoxybenzoyl), (isobutyryl), OSiEt3 (triethylsilyl ether, TES), OSi( i Pr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2tBu (tert-butyldimethylsilyl ether, TBS), OSiPh2 t Bu (tert-butyldiphenylsilyl ether, TBDPS), OSO2Me (methylsulfonyl), (4-toluenesulfonyl, tosyl), (4-nitrobenzenesulfonyl, nitrobenzenesulfonyl (nosyl)) and OSO2CF3 (trifluoromethanesulfonyl). In some cases, OPG is 4-bromobenzoyl.

[0021] In various embodiments, R 2 is a protected aldehyde. In some cases, the protected aldehyde is selected from the group consisting of:

[0022] In some cases, R 2 yes

[0023] In various embodiments, Compound C has the following structure:

[0024] In various embodiments, compound D has the following structure:

[0025] In various embodiments, the reducing agent is selected from the group consisting of borohydride, borane, silane, Hantzsch ester, formic acid / amine base / metal catalyst, and hydrogen / metal catalyst. In some cases, the reducing agent is selected from the group consisting of NaBH(OAc)3, NaBH3CN, NaBH4, picolinyl borane (pic-BH3), borane tetrahydrofuran (BH3-THF), decaborane (B 10 H 14 ), borane dimethyl sulfide (BH3-S(Me)2), N-heterocyclic carbene borane (NHC-borane), triethylsilane, phenylsilane, diphenylsilane, H2 / Pd, H2 / Rh, H2 / Ir, H2 / Ru, formic acid / triethylamine / Rh, formic acid / triethylamine / Ir, and formic acid / triethylamine / Ru. In some cases, the reducing agent is NaBH(OAc)3.

[0026] In various embodiments, the organic solvent is selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, tetrahydrofurfuryl alcohol, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, 1,2-dimethoxyethane, 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), and combinations thereof. In some cases, the organic solvent is selected from the group consisting of toluene, THF, DCM, and combinations thereof. In some cases, the organic solvent is toluene.

[0027] In various embodiments, compound B and compound C are present in a molar ratio of B: C of 1: 1 to 1: 2. In some cases, the molar ratio of B: C is 1: 1.1.

[0028] In various embodiments, compound B and the reducing agent are present in a molar ratio of 1:1 to 1:2.25. In some cases, the molar ratio of compound B to the reducing agent is 1:1.25.

[0029] In various embodiments, each of step (a) and step (b) occurs at a temperature of 10° C. to 40° C. In some cases, each of step (a) and step (b) occurs at a temperature of 20° C.

[0030] In various embodiments, the mixing of step (a) occurs for 1 minute to 1 hour. In some cases, the mixing of step (a) occurs for 30 minutes.

[0031] In various embodiments, the reducing agent is added to the slurry within 60 seconds. In various embodiments, the reducing agent is added to the slurry over 10 minutes to 1 hour. In various embodiments, the reducing agent is added to the slurry in two or more equal portions. In some cases, the reducing agent is added to the slurry in four equal portions. In some cases, the equal portions are added 15 minutes apart.

[0032] In various embodiments, the mixing of step (b) occurs for 5 hours to 20 hours. In some cases, the mixing of step (b) occurs for 16 hours.

[0033] In various embodiments, steps (a) and (b) are performed sequentially in a single reaction vessel.

[0034] In various embodiments, the methods further include: (c) extracting compound D from the mixture of step (b). In some cases, the extraction is performed by crystallizing compound D. In some cases, the crystallization is performed with an organic solvent selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, tetrahydrofurfuryl alcohol, heptane, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, dimethoxyethane (DME), 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), and combinations thereof. In some cases, the crystallization is performed with toluene and heptane.

[0035] In various embodiments, the methods further comprise using Compound D to synthesize Compound A1, or a salt or solvate thereof:

[0036] In various embodiments, the methods further comprise using Compound D to synthesize a salt of Compound A2, or a solvate thereof:

[0037] Other aspects and advantages will be apparent to those of ordinary skill in the art by reading the following detailed description.While the following description includes specific embodiments, it should be understood that this disclosure is illustrative and is not intended to limit the invention to the specific embodiments described herein. DETAILED DESCRIPTION

[0038] Provided herein are methods for synthesizing Mcl-1 inhibitors and corresponding vinyl protected alcohol intermediates. Specifically, provided herein are methods for synthesizing (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0 3, 6 .0 19,24 ]pentacosa[8,16,18,24]tetraene]-15'-one 13',13'-dioxide (Compound A1), or a salt or solvate thereof, and use thereof in the synthesis of (1S,3'R,6'R,7'R,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-7'-((9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-ylmethyl)-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0 3,6 .0 19,24 ]pentacosa[8,16,18,24]tetraene]-15'-one 13',13'-dioxide (Compound A2) or a salt or solvate thereof:

[0039]

[0040] U.S. Patent No. 9,562,061, which is incorporated herein by reference in its entirety, discloses Compound A1, or a salt or solvate thereof as a Mcl-1 inhibitor and provides a method for preparing the same. The disclosure of Compound A1 salts and solvates from U.S. Patent No. 9,562,061 is incorporated by reference in its entirety. The patent also discloses a method for synthesizing a vinyl alcohol intermediate compound shown below for use in the synthesis of Compound A1.

[0041] '061 Patented Vinyl Alcohol Intermediates

[0042] U.S. Patent No. 10,300,075, which is incorporated herein by reference in its entirety, discloses Compound A2, or a salt or solvate thereof, as a Mcl-1 inhibitor and provides a method for preparing the same. The disclosure of Compound A2 salts and solvates from U.S. Patent No. 10,300,075 is incorporated by reference in its entirety. The patent also discloses a method for synthesizing the vinyl alcohol intermediate compound shown above for use in the synthesis of Compound A2.

[0043] The '061 patent generally describes a procedure for preparing a vinyl alcohol intermediate as shown in Scheme 1 below, which is adapted from the disclosure in column 49 of the '061 patent. The '061 patent describes the reaction of cyclobutane carboxaldehyde (Intermediate II) with an oxazepine in a solvent at a temperature below room temperature, preferably 0°C. (oxazepine) (intermediate I) is combined. Sodium cyanoborohydride is added, and the mixture is added to a sodium hydroxide solution to provide intermediate III. Advantageously, the methods described herein provide an improved synthetic route as compared to General Procedure 1 of the '061 patent. The methods described herein can be performed under ambient conditions (e.g., room temperature) and with milder reagents. In addition, as compared to the vinylcyclobutyl intermediate of the '061 patent, the methods can utilize a crystalline vinylcyclobutyl intermediate, which allows for improved separation, storage, and purity throughout the methods.

[0044] Scheme 1 - General Procedure 1 of the '061 Patent

[0045]

[0046] The '061 patent further describes a method for synthesizing a vinyl alcohol intermediate in which a fragment including a cyclobutyl moiety has been reacted with a benzoxazepine. After the moieties are linked, vinyl groups are added to the compounds. For example, Scheme 2, shown below and adapted from the disclosure of columns 66-71 of the '061 patent, represents a general method for synthesizing vinyl alcohol as described in the '061 patent. The '061 patent describes the separation of each intermediate compound prior to use in the next synthetic step. Advantageously, the methods described herein require fewer steps than the methods of the '061 patent and do not require the separation of any intermediates. In addition, as compared to the '061 patent, the methods described herein provide convergent fragment assembly of compounds A1 and A2, provide excellent purity distributions, provide highly crystalline intermediates, thereby improving stability, and have overall higher yields.

[0047] Scheme 2 - Synthesis of Vinyl Alcohol Intermediates of the '061 Patent

[0048]

[0049] Described herein are methods for synthesizing Compound D or a salt or solvate thereof:

[0050]

[0051] It includes (a) mixing compound B or its salt and compound C in an organic solvent to form a slurry, and (b) mixing the slurry of step (a) and a reducing agent to form a mixture containing compound D, as discussed in detail below. As will be appreciated, the disclosed method involves forming an intermediate compound formed by reacting the amine of compound B with the aldehyde or protected aldehyde of compound C, and then reducing the intermediate to form the nitrogen-carbon bond of compound D. The method for forming compound D disclosed herein can be carried out sequentially in a single reaction vessel without isolating the intermediate formed between compound B and C in step (a). Optionally, compound D can be isolated via extraction (e.g., crystallization) to form a crystalline compound D, which can be used in further reactions in the preparation of compound A.

[0052] Step A

[0053] The method of the present disclosure comprises mixing compound B or its salt and compound C in an organic solvent to form a slurry. It should be understood that the mixing of compounds B and C in step (a) forms an intermediate compound that is not isolated from the coupling of the nitrogen of compound B with the aldehyde or protected aldehyde of compound C.

[0054] As provided herein, Compound B has or a salt thereof, wherein R 1 Is H or C 1-6 In some embodiments, R 1 is H. In other embodiments, R 1 It is C 1-6 As used herein, the term "alkyl" refers to straight chain and branched chain saturated hydrocarbon groups. n It means a group having "n" carbon atoms. For example, C3 alkyl means an alkyl group having 3 carbon atoms. 1-6 Alkyl refers to an alkyl group having a carbon atom number covering the entire range (i.e., 1 to 6 carbon atoms) and all subgroups (e.g., 2-6, 1-5, 1-4, 3-6, 3-5, 1, 2, 3, 4, 5, and 6 carbon atoms). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl (2-methylpropyl), tert-butyl (1,1-dimethylethyl), n-pentyl, and n-hexyl. In some embodiments, R 1 It is methyl, ethyl, n-propyl, or tert-butyl.

[0055] In some embodiments, Compound B is a salt. A salt of Compound B can be prepared, for example, by making a free base (i.e., 1Compound B (when it is H) is reacted with a suitable organic or inorganic acid, and the salt thus formed is optionally separated to prepare. The non-limiting examples of suitable salts include hydrobromate, hydrochloride, sulfate, bisulfate, sulfonate, camphorsulfonate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, mesylate, glucoheptonate, lactobionate, lauryl sulfonate and amino acid salts etc. In certain embodiments, compound B is camphorsulfonate (i.e., compound B in its free acid form is reacted with camphorsulfonic acid).

[0056] As provided herein, Compound C has The structure of R 2 is CHO (i.e., an aldehyde) or a protected aldehyde, and OPG is an alcohol protecting group. 2 is CHO. In other embodiments, R 2 It is a protected aldehyde.

[0057] The term "protected aldehyde" or "aldehyde protecting group" refers to any protecting group used to mask the aldehyde functional group. Aldehyde protecting groups include acetals and hemiacetals. Acetals and hemiacetals can be made from C 1-8 Alcohol or C 2-8 In some cases, the protected aldehyde is a five-membered or six-membered cyclic acetal formed by condensation of an aldehyde with ethylene glycol or propylene glycol. In some cases, the protected aldehyde is an imine or hydroxyimine. In some cases, the protected aldehyde comprises a bisulfite or a benzotriazole. In some embodiments, the protected aldehyde is selected from the group consisting of:

[0058] In some embodiments, the protected aldehyde is In some embodiments, the protected aldehyde is The counter ion is, for example, a sodium ion.

[0059] Alcohol protecting groups are groups that cover hydroxyl functional groups, and are well known in the art. The preparation of compounds may relate to the protection and deprotection of various hydroxyl groups. Those skilled in the art can easily determine the needs of protection and deprotection, and the selection of suitable protecting groups. Protective group chemistry can be found in, for example, Greene, et al., Protective Groups in Organic Synthesis [protective groups in organic synthesis], the 4th edition, Wiley & Sons, 2007, which is incorporated herein by reference in its entirety. Alcohol protecting groups described herein and the adjustment of formation and cleavage methods can be adjusted as needed according to various substituents. In some cases, the alcohol protecting group OPG is selected from the group consisting of: ether, acetal or ketal, acyl, sulfonyl and silyl ether.

[0060] In certain embodiments, OPG is an ether. The ether protecting group comprises a substituted or unsubstituted alkyl moiety attached to the oxygen from a protected hydroxyl group (e.g., masked as an ether). The example of suitable ethers includes but is not limited to methoxy, ethoxy, propoxy, butoxy, methoxymethyl acetal (MOM), 2-methoxyethoxymethyl ester (MEM), ethoxyethyl acetal (EE) and methoxypropyl ether (MOP). Other examples of envisioned ethers include but are not limited to benzyloxymethyl acetal (BOM), benzyl ether (Bn), 4-methoxybenzyl ether (PMB) and 2-naphthyl methyl ether (Nap).

[0061] In some embodiments, OPG is an acetal or ketal. The acetal as a protecting group has The general structure of and can be an acetal (as the OR' option, where R' is, for example, an alkyl group) or a hemiacetal (as the OH option), where RO is derived from the protected hydroxyl group and PG' is the remainder of the (hemi)acetal protecting group. Ketals as protecting groups have The general structure of (where RO is derived from a protected hydroxyl group), and may be as a ketal (as an OR' option, where R' is, for example, an alkyl group) or a hemiketal (as an OH option, and each PG' is derived from the remainder of the (hemi)ketal protecting group), masking the hydroxyl group (i.e., R-OH), and may be substituted or unsubstituted. Examples of suitable acetals include, but are not limited to, tetrahydropyran acetal (THP).

[0062] In some embodiments, OPG is an acyl group. As used herein, the term "acyl group" refers to an alcohol protecting group in which the oxygen atom of the alcohol is bound to the acyl group. Wherein RO is derived from the protected hydroxyl group and PG' is derived from the remainder of the acyl protecting group. Examples of suitable acyl groups include, but are not limited to, acetyl (Ac), pivaloyl (Piv), benzoyl (Bz), 4-bromobenzoyl (Br-Bz), 4-fluorobenzoyl, 4-chlorobenzoyl, 4-iodobenzoyl, 4-nitrobenzoyl, 4-phenylbenzoyl, 1-naphthoyl ester, 2-naphthoyl ester, 4-methoxybenzoyl, and isobutyryl.

[0063] In some embodiments, OPG is a silyl ether. As used herein, the term "silyl ether" refers to an alcohol protecting group in which the oxygen atom of the alcohol is bonded to a silyl ether group. Wherein RO is derived from the protected hydroxyl group, and each PG' is derived from the remainder of the silyl ether protecting group. Examples of suitable silyl ethers include, but are not limited to, triethylsilyl ether (TES), triisopropylsilyl ether (TIPS), trimethylsilyl ether (TMS), tert-butyldimethylsilyl ether (TBS), and tert-butyldiphenylsilyl ether (TBDPS).

[0064] In some embodiments, OPG is a sulfonyl protecting group. As used herein, the term "sulfonyl protecting group" refers to an alcohol protecting group in which the oxygen atom of the alcohol is bound to a sulfonyl group. wherein RO is derived from the protected hydroxyl group and PG' is derived from the remainder of the sulfonyl protecting group. In some embodiments, the sulfonyl protecting group is selected from the group consisting of: methanesulfonyl, toluenesulfonyl, nosyl and trifluoromethanesulfonyl.

[0065] In some embodiments, the OPG is selected from the group consisting of: (methoxy), (tert-butyl ether), (methoxymethyl acetal, MOM), (2-methoxyethoxymethyl ether, MEM), (ethoxyethyl acetal, EE), (methoxypropyl acetal, MOP), (tetrahydropyranyl acetal, THP), (benzyloxymethyl acetal, BOM), (benzyl ether, Bn), (4-methoxybenzyl ether, PMB), (2-naphthyl methyl ether, Nap), (Acetyl, Ac), Pivaloyl (Piv), (benzoyl, Bz), (4-bromobenzoyl, Br-Bz), (4-fluorobenzoyl), (4-chlorobenzoyl), (4-iodobenzoyl), (4-nitrobenzoyl), (4-phenylbenzoyl), (1-naphthoyl ester), (2-naphthoyl ester), (4-methoxybenzoyl), (isobutyryl), OSiEt3 (triethylsilyl ether, TES), OSi( i Pr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2tBu (tert-butyldimethylsilyl ether, TBS), OSiPh2 t Bu (tert-butyldiphenylsilyl ether, TBDPS), OSO2Me (methylsulfonyl), (4-toluenesulfonyl, tosyl), (4-nitrobenzenesulfonyl, nitrobenzenesulfonyl (nosyl)) and OSO2CF3 (trifluoromethanesulfonyl). In some embodiments, OPG is 4-bromobenzoyl.

[0066] In some embodiments, OPG is 4-bromobenzoyl and R 1 yes That is, compound C has structure.

[0067] The mixing of step (a) of compound B and C is carried out in the presence of an organic solvent. Compound B and compound C may be present in the organic solvent in a molar ratio of B:C of 1:1 to 1:2, for example, a molar ratio of at least 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, or 1:1.5, and / or a molar ratio of up to 1:2, 1:1.9, 1:1.7, 1:1.6, 1:1.5, or 1:1.4, such as 1:1 to 1:1.5, 1:1 to 1:1.4, or 1:1.1 to 1:1.3. In some embodiments, the molar ratio of compound B to compound C is 1:1.1.

[0068] The organic solvent of step (a) is selected from the group consisting of: non-polar aromatic solvent, ether solvent, chlorinated solvent, alcohol solvent, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), dimethyl carbonate, and combinations thereof. Non-limiting examples of non-polar aromatic solvents include toluene, benzene, xylene, chlorobenzene, fluorobenzene, naphthalene and trifluorotoluene. Non-limiting examples of ether solvents include tetrahydrofuran (THF), tetrahydropyran, tetrahydrofurfuryl alcohol, diethyl ether, dibutyl ether, diisopropyl ether, methyl tert-butyl ether (MTBE), 1,2-dimethoxyethane, 1,4-dioxane, 2-methyltetrahydrofuran (2-MeTHF) and cyclopentyl methyl ether. Non-limiting examples of chlorinated solvents include 1,2-dichloroethane, chloroform, carbon tetrachloride and methylene dichloride. Non-limiting examples of alcohol solvents include methanol, ethanol, propanol, 2-propanol and tert-butyl alcohol.

[0069] In some embodiments, the organic solvent is selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, tetrahydrofurfuryl alcohol, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, 1,2-dimethoxyethane, 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), and combinations thereof. In some embodiments, the organic solvent is selected from the group consisting of toluene, THF, DCM, and combinations thereof. In some embodiments, the organic solvent is toluene.

[0070] The solvent can be included in an amount of 5 L / kg of compound B to 25 L / kg of compound B, for example, at least about 5, 10, 15 or 20 L / kg of compound B and / or up to about 25, 20, 25 or 10 L / kg of compound B, such as 5 L / kg to 20 L / kg, 5 L / kg to 15 L / kg, or 5 L / kg to 10 L / kg. In some embodiments, the solvent is present in an amount of 10 L / kg of compound B.

[0071] In some embodiments, step (a) further comprises (Camphorsulfonic acid) is mixed with compounds B and C in an organic solvent. As described herein, camphorsulfonic acid can be used to prepare a salt form of compound B. Advantageously, the salt form of compound B can be formed in situ and does not need to be isolated prior to use in step (a) of the methods described herein.

[0072] Step (a) can occur at a temperature of 10° C. to 40° C., for example, at least 10° C., 12° C., 15° C., 17° C., 20° C., 22° C., 25° C., 27° C., or 30° C., and / or up to 40° C., 37° C., 35° C., 32° C., 30° C., 27° C., 25° C., 22° C., or 20° C., such as 10° C. to 30° C., 12° C. to 27° C., 15° C. to 25° C., or 17° C. to 22° C. In some embodiments, step (a) occurs at a temperature of 20° C.

[0073] The mixing of step (a) can occur for 1 minute to 1 hour, for example, at least 1, 5, 10, 15, 20, 25, 30, 35, or 40 minutes and / or up to 60, 55, 50, 45, 40, 35, 30, 25, or 20 minutes, such as 5 to 45 minutes, 10 to 40 minutes, 15 to 40 minutes, 20 to 45 minutes, or 25 to 35 minutes. In some embodiments, the mixing of step (a) occurs for 30 minutes.

[0074] Step B

[0075] The method of the present disclosure includes mixing the slurry of step (a) and a reducing agent to form a mixture comprising compound D. Step (b) may occur in the same or different reaction vessel as step (a). In some embodiments, step (b) occurs in the same reaction vessel as step (a).

[0076] As provided herein, compound D is Where R 1 Each of OPG and R is as described herein. 1 is H and OPG is 4-bromobenzoyl, i.e., compound D has the structure

[0077] The reducing agent is any reagent that will reduce the nitrogen-carbon double bond formed between compound B and C in step (a). The reducing agent can be, for example, a metal hydride, a hydrogen / metal catalyst, an organometallic reagent, or an electron donor used in combination with a proton, wherein the electron is provided by a cathode or a metal selected from Li, Na, K, Mg, Zn, Fe, and Al. Metal hydrides include hydrides of boron and aluminum. Examples of hydrides of boron or aluminum include NaBH4, NaB(CN)H3, NaBH(OAc)3, LiAlH4, LiAlH(Otert-Bu)4, LiBH4, LiBHEt3, and LiBH(sec-Bu)3. In some cases, the reducing agent is selected from the group consisting of: borohydride, borane, silane, Hans (Hantzsch) ester, formic acid / amine base / metal catalyst, and hydrogen / metal catalyst. Hans esters, 1,4-dihydrobenzene, isopropanol, formic acid and ammonium formate are transfer hydrogenation agents and are sources of hydrogen because they can transfer hydride ions and protons. Reactions with these transfer hydrogenation agents can be carried out in the absence of metals, i.e., in the absence of metal catalysts.

[0078] In some embodiments, the reducing agent is a borohydride. Examples of suitable borohydrides include, but are not limited to, NaBH(OAc)3, NaBH3CN, NaBH4. In some embodiments, the reducing agent is NaBH(OAc)3.

[0079] In some embodiments, the reducing agent is borane. Examples of suitable boranes include, but are not limited to, picolinyl borane (pic-BH3), borane tetrahydrofuran (BH3-THF), decaborane (BH3-THF), 10 H 14 ), borane dimethyl sulfide (BH3-S(Me)2) and N-heterocyclic carbene borane (NHC-borane). An example of NHC-borane is 1,3-dimethylimidazol-2-ylidene borane (diMe-Imd-BH3).

[0080] In some embodiments, the reducing agent is a silane. Examples of suitable silanes include, but are not limited to, triethylsilane, phenylsilane, diphenylsilane, trichlorosilane, triphenylsilane, (tri)trimethylsilane, and phenylmethylsilane.

[0081] In some embodiments, the reducing agent is a Hans ester. Examples of suitable Hans esters include, but are not limited to as well as

[0082] In some embodiments, the reducing agent is formic acid / amine base / metal catalyst. Examples of suitable amine bases include tertiary amine bases, such as triethylamine and diisopropylethylamine. Examples of suitable metal catalysts include, but are not limited to, palladium (Pd), iridium (Ir), ruthenium (Ru), and rhodium (Rh). Examples of suitable formic acid / amine base / metal catalysts include, but are not limited to, formic acid / triethylamine / Ir, formic acid / triethylamine / Ru, and formic acid / triethylamine / Rh.

[0083] In some embodiments, the reducing agent is a hydrogen / metal catalyst, including but not limited to H2 / Pd, H2 / Rh, H2 / Ir, and H2 / Ru.

[0084] In some embodiments, the reducing agent is selected from the group consisting of NaBH(OAc)3, NaBH3CN, NaBH4, picolinyl borane (pic-BH3), borane tetrahydrofuran (BH3-THF), decaborane (B 10 H 14 ), borane dimethyl sulfide (BH3-S(Me)2), N-heterocyclic carbene borane (NHC-borane), triethylsilane, phenylsilane, diphenylsilane, H2 / Pd, H2 / Rh, and H2 / Ru, formic acid / triethylamine / Rh, formic acid / triethylamine / Ir, and formic acid / triethylamine / Ru.

[0085] Compound B and the reducing agent can be present in a molar ratio of 1:1 to 1:2.25, for example, at least 1:1, 1:1.25, 1:1.5, 1:1.75 or 1:2 and / or up to 1:2.25, 1:1.2, 1:1.75, 1:1.5, or 1:1.25, such as 1:1 to 1:2, 1:1 to 1:1.75, or 1:1 to 1:1.5. In some embodiments, the molar ratio of compound B to the reducing agent is 1:1.25.

[0086] The reducing agent can be added to the slurry of step (a) in a single addition (i.e., all at once) or in increments (i.e., parts) over time. It should be understood that when large-scale reactions (e.g., kilogram scale materials) are involved, the practice of adding the reducing agent "all at once" to the slurry may take longer than, for example, 1 second. Thus, in some embodiments, the reducing agent is added to the slurry within 60 seconds and in some cases within 30 seconds or within 10 seconds, and is considered to be added to the slurry all at once. When the reducing agent is not added all at once, it can be added in batches or continuously added over a longer time period. In some embodiments, over 10 minutes to 1 hour, for example, over at least 10, 15, 20, 25, 30, 35, or 40 minutes and / or up to 60, 55, 50, 45, 40, 35, 30, or 25 minutes, such as 10 to 45 minutes, 15 to 30 minutes, or 20 to 30 minutes, the reducing agent is added to the slurry. In some embodiments, the reducing agent is added to the slurry in two or more equal portions. In some embodiments, the reducing agent is added to the slurry in four equal portions. In some embodiments, each of the two or more equal portions (e.g., four equal portions) is added 15 minutes apart.

[0087] Step (b) can occur at a temperature of 10° C. to 40° C., for example, at least 10° C., 12° C., 15° C., 17° C., 20° C., 22° C., 25° C., 27° C., or 30° C., and / or up to 40° C., 37° C., 35° C., 32° C., 30° C., 27° C., 25° C., 22° C., or 20° C., such as 12° C. to 35° C., 15° C. to 30° C., 17° C. to 25° C., or 20° C. to 25° C. In some embodiments, step (b) is performed at a temperature of 20° C.

[0088] The mixing of step (b) can occur for 5 hours to 20 hours, for example at least 5, 7, 10, 12, 16 or 15 hours and / or up to 20, 17, 16, 15, 12, 10 or 7 hours, such as 10 to 20 hours, 12 to 20 hours, 12 to 17 hours, or 15 to 17 hours. In some embodiments, mixing occurs for 16 hours.

[0089] Step C

[0090] In some embodiments, the method of the present disclosure may further include extracting compound D from the mixture of step (b). In some embodiments, compound D is extracted by crystallizing from the mixture. Crystallization can be carried out with an organic solvent selected from the group consisting of: toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, tetrahydrofurfuryl alcohol, heptane, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, dimethoxyethane (DME), 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), and combinations thereof. In some embodiments, toluene and heptane are used to crystallize compound D from a mixture. In some cases, the seed crystals of compound D are added during crystallization to help form compound D crystals. In some cases, the crystals of compound D are filtered and dried.

[0091] Compounds A1 and A2 can be synthesized using the method for synthesizing compound D. Compound A1, or a salt or solvate thereof, can be synthesized using compound D as shown in Scheme 3 below. Compound A2, or a salt or solvate thereof, can be synthesized using compound D as shown in Scheme 4 below.

[0092] Scheme 3 - Conversion of Compound D to Compound A1

[0093]

[0094] As shown in Scheme 3 and described in U.S. Pat. No. 9,562,061, Compound D can be used to synthesize Compound A1 and its salts and solvates. The synthesis of sulfonamide EE22 is disclosed in U.S. Pat. No. 9,562,061. Compound EE22 and D can be reacted to form Compound E. Cyclization and deprotection of Compound E provide Compound F, which can then be methylated to provide Compound A1 as described in U.S. Pat. No. 9,562,061.

[0095] Scheme 4 - Conversion of Compound D to Compound A2

[0096]

[0097] As shown in Scheme 4 and described in U.S. Patent No. 10,300,075, Compound D can be used to synthesize Compound A2 and its salts and solvates. As described above with respect to Scheme 3, the synthesis of sulfonamide EE22 is disclosed in U.S. Patent No. 9,562,061. Compound EE22 and D can be reacted to form Compound E, which can be cyclized to provide Compound F. Compound F can then be oxidized to provide Compound G, as disclosed in U.S. Patent No. 10,300,075. Alternatively, Compound E can be oxidized to provide Compound F in an uncyclized form, which can then be cyclized to provide Compound G. Compound G can then be epoxidized to Compound H using the procedure disclosed in U.S. Patent No. 10,300,075. Compound H can then be reacted with bicyclic compound I to provide Compound J. Finally, methylation of Compound J provides Compound A2 as disclosed in U.S. Patent No. 10,300,075.

[0098] In some embodiments, the method further comprises using Compound D to synthesize Compound A1 or a salt or solvate thereof:

[0099]

[0100] In some embodiments, the method further comprises using Compound D to synthesize Compound A2 or a salt or solvate thereof:

[0101]

[0102] It should be understood that while the disclosure is to be read in conjunction with its detailed description, the foregoing description and the following examples are intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.

[0103] Examples

[0104] The following examples are provided for illustration and are not intended to limit the scope of the present invention.

[0105] Example 1

[0106]

[0107] 25.0g of compound B (1.0 equivalent, 43.4mmol) was loaded into a 500ml glass-lined jacketed reactor, followed by 21.9g of compound C (1.1 equivalent, 47.7mmol, 70.4wt%) and 250ml of toluene (10L / kg). The resulting slurry mixture was stirred at 20°C for 30min. Then, 0.25 equivalent portions of NaBH(OAc)3 (11.5g, 1.25 equivalents) were loaded into the reactor at 20°C, with each portion loaded at least 15 minutes apart. The reaction was stirred at 20°C for ≥5 hours until LC analysis confirmed that compound B was completely consumed. An aqueous solution of NaCl and NaHCO3 was slowly loaded into the reaction mixture to control the observed gas evolution. The batch was stirred at 20°C for >30 minutes. The aqueous phase was removed after phase separation. The reactor containing the organic phase was charged with an aqueous H3PO4 solution, and the resulting mixture was stirred at 20°C for>15 minutes. The aqueous phase was removed after phase separation. The H3PO4 aqueous solution washing procedure was repeated twice more. An aqueous NaCl solution was charged into the reactor containing the organic phase, and the mixture was stirred at 20°C for>15 minutes. The aqueous phase was removed after phase separation. The batch was then concentrated under reduced pressure at ≤55°C, and the batch was then cooled to 20°C. Compound D seeds were charged into the reactor to induce crystallization, and the slurry was kept at 20°C for>1 hour. Heptane was then charged into the reactor. After addition, the suspension was stirred at 20°C for>1 hour. After filtering and washing with 2 / 1 heptane / toluene and drying under vacuum at 40°C, compound D was obtained. Compound D was obtained in two steps with 85.5wt%, 85.0% isolated yield.

[0108] Compound D: 1H NMR (600MHz, CDCl3) δ7.86(d,J=8.6Hz,2H),7.64(d,J=8.5Hz,1H),7.50(d,J=8.6Hz ,2H),7.47(dd,J=8.2,1.9Hz,1H),7.44(d,J=1.9Hz,1H),7.16(dd,J=8.5,2.3Hz,1H) ,7.08(d,J=2.3Hz,1H),6.93(d,J=8.2Hz,1H),5.84(ddd,J=17.1,10.6,6.4Hz,1H), 5.49(bt,J=6.4Hz,1H),5.36(dt,J=17.1,1.2Hz,1H),5.22(dt,J=10.6,1.2Hz,1H),4 .12(d,J=12.1Hz,1H),4.08(d,J=12.1Hz,1H),3.59(dd,J=14.8,4.1Hz,1H),3.52(d ,J=14.4Hz,1H),3.35(dd,J=14.8,9.0Hz,2H),3.32(d,J=14.4Hz,1H),2.78-2.75(m, 1H),2.75-2.71(m,2H),2.47(qui,J=8.5Hz,1H),2.12-2.02(m,1H),2.00-1.92(m,1H ),1.93-1.85(m,2H),1.85-1.77(m,1H),1.78-1.69(m,2H),1.56(bt,J=11.0Hz,1H); 13 CNMR (151 MHz, CDCl3) δ 171.8, 165.1, 153.7, 141.0, 139.0, 138.8, 134.3, 132.1, 131.7, 131.0, 129.5, 129.1, 128.6, 128.1, 126.6, 123.7, 121.7, 120.8, 117.5, 117.0, 79.4, 78.0, 60.9, 58.8, 43.0, 41.8, 36.2, 30.2, 29.0, 25.9, 21.2, 19.0. LRMS (ESI): calculated: 650; found: 650.1.

Claims

1. A method for synthesizing compound D: It includes: (a) mixing compound B, or a salt thereof, and compound C in an organic solvent to form a slurry, wherein the organic solvent is selected from the group consisting of a non-polar aromatic solvent, an ether solvent, a chlorinated solvent, an alcohol solvent, acetonitrile, dimethylformamide (DMF), dimethyl carbonate, dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), and a combination thereof: as well as (b) mixing the slurry of step (a) and a reducing agent to form a mixture comprising compound D; in: OPG is an alcohol protecting group selected from the group consisting of an ether, an acetal or ketal, an acyl group, a sulfonyl group, and a silyl ether; R 1 Is H or C 1-6 Alkyl; and R 2 It is a protected aldehyde.

2. The method of claim 1, further comprising: In step (a) the organic solvent is mixed.

3. The method of claim 2, wherein: Compound B is a salt.

4. The method according to claim 1 or 2, wherein: R 1 It's H.

5. The method according to claim 1 or 2, wherein: R 1 It is methyl, ethyl, n-propyl, or tert-butyl.

6. The method according to any one of claims 1 to 5, wherein: OPG is selected from the group consisting of: (methoxy), (tert-butyl ether), (methoxymethyl acetal, MOM), (2-methoxyethoxymethyl ether, MEM), (ethoxyethyl acetal, EE), (methoxypropyl acetal, MOP), (tetrahydropyranyl acetal, THP), (benzyloxymethyl acetal, BOM), (benzyl ether, Bn), (4-methoxybenzyl ether, PMB), (2-naphthyl methyl ether, Nap), (Acetyl, Ac), (pivaloyl, Piv), (benzoyl, Bz), (4-bromobenzoyl, Br-Bz), (4-fluorobenzoyl), (4-chlorobenzoyl), (4-iodobenzoyl), (4-nitrobenzoyl), (4-phenylbenzoyl), (1-naphthoyl ester), (2-naphthoyl ester), (4-methoxybenzoyl), (isobutyryl), OSiEt3 (triethylsilyl ether, TES), OSi( i Pr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2 t Bu (tert-butyldimethylsilyl ether, TBS), OSiPh2 t Bu (tert-butyldiphenylsilyl ether, TBDPS), OSO2Me (methylsulfonyl), (Tosyl), (nitrobenzenesulfonyl) and OSO2CF3 (trifluoromethanesulfonyl).

7. The method of claim 6, wherein: OPG is 4-bromobenzoyl.

8. The method of any one of claims 1 to 7, wherein R 2 It is a protected aldehyde.

9. The method of claim 8, wherein: The protected aldehyde is selected from the group consisting of: as well as 10. The method according to claim 8 or 9, wherein: R 2 yes 11. The method of claim 10, wherein: Compound C has the following structure:

12. The method according to any one of claims 1 to 4, wherein: Compound D has the following structure:

13. The method according to any one of claims 1 to 12, wherein: The reducing agent is selected from the group consisting of borohydrides, boranes, silanes, Hans esters, formic acid / amine base / metal catalyst, and hydrogen / metal catalyst.

14. The method of claim 13, wherein: The reducing agent is selected from the group consisting of: NaBH(OAc)3, NaBH3CN, NaBH4, picolinyl borane (pic-BH3), borane tetrahydrofuran (BH3-THF), decaborane (B 10 H 14 ), borane dimethyl sulfide (BH3-S(Me)2), N-heterocyclic carbene borane (NHC-borane), triethylsilane, phenylsilane, diphenylsilane, H2 / Pd, H2 / Rh, H2 / Ir, H2 / Ru, formic acid / triethylamine / Rh, formic acid / triethylamine / Ir, and formic acid / triethylamine / Ru.

15. The method of claim 14, wherein: The reducing agent is NaBH(OAc)3.

16. The method according to any one of claims 1 to 15, wherein: The organic solvent is selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, tetrahydrofurfuryl alcohol, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, 1,2-dimethoxyethane, 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), and combinations thereof.

17. The method of claim 16, wherein: The organic solvent is selected from the group consisting of toluene, THF, DCM, and combinations thereof.

18. The method of claim 17, wherein: The organic solvent is toluene.

19. The method according to any one of claims 1 to 18, wherein: Compound B and compound C are present in a molar ratio of B:C of 1:1 to 1:

2.

20. The method of claim 19, wherein: The molar ratio of B:C is 1:1.

1.

21. The method of any one of claims 1 to 20, wherein: Compound B and the reducing agent are present in a molar ratio of 1:1 to 1:2.

25.

22. The method of claim 21, wherein: The molar ratio of compound B to the reducing agent is 1:1.

25.

23. The method of any one of claims 1 to 22, wherein: Each of step (a) and step (b) occurs at a temperature of 10°C to 40°C.

24. The method of claim 23, wherein: Each of step (a) and step (b) occurs at a temperature of 20°C.

25. The method of any one of claims 1 to 24, wherein: This mixing of step (a) occurs for 1 minute to 1 hour.

26. The method of claim 25, wherein: This mixing of step (a) occurred for 30 minutes.

27. The method of any one of claims 1 to 26, wherein: The reducing agent was added to the slurry within 60 seconds.

28. The method of any one of claims 1 to 26, wherein: The reducing agent is added to the slurry over 10 minutes to 1 hour.

29. The method of claim 28, wherein: The reducing agent is added to the slurry in two or more equal portions.

30. The method of claim 29, wherein: The reducing agent was added to the slurry in four equal portions.

31. The method of claim 29 or 30, wherein: These aliquots were added at 15 minute intervals.

32. The method of any one of claims 1 to 31, wherein: This mixing of step (b) occurs for 5 to 20 hours.

33. The method of claim 32, wherein: This mixing of step (b) occurred for 16 hours.

34. The method of any one of claims 1 to 33, wherein: Steps (a) and (b) are performed sequentially in a single reaction vessel.

35. The method of any one of claims 1 to 34, further comprising (c) extracting compound D from the mixture of step (b).

36. The method of claim 35, wherein: The extraction is carried out via crystallization of compound D.

37. The method of claim 36, wherein: The crystallization is carried out with an organic solvent selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, tetrahydrofurfuryl alcohol, heptane, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, dimethoxyethane (DME), 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, methyl tert-butyl ether (MTBE), 2-methyltetrahydrofuran (2-MeTHF), and combinations thereof.

38. The method of claim 37, wherein: The crystallization is carried out with toluene and heptane.

39. The method of any one of claims 1 to 38, further comprising using Compound D to synthesize Compound A1, or a salt or solvate thereof:

40. The method of any one of claims 1-38, further comprising using Compound D to synthesize Compound A2, or a salt of a solvate thereof: